ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

icotrokinra

Also written as “JNJ-77242113”, “Icotrokinra” and “PN-235”.

Its studies are mostly in Psoriasis · Arthritis, Psoriatic · Colitis, Ulcerative · Crohn Disease, led by 2 companies.

Drug pageIcotrokinra: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 18, 202314 company-led studies, 7 open or runningLicense: Protagonist Therapeutics → Johnson & Johnson, 2017Next primary completion: Feb 10, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnsonits history only137 open or runningphase 3since Oct 18, 2023Sep 21, 2021Feb 10, 2027phase 3 · NCT06807424
Protagonist Therapeutics10 open or runningphase 1since Oct 29, 2020Oct 29, 2020none ahead

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of Protagonist Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. 2017Johnson & Johnson licensed it from Protagonist TherapeuticsLicenseWorldwide rights from phase 2 on · agreed · Johnson & Johnson
  2. Oct 29, 2020First study: phase 1 study in Healthy VolunteersFirst studyNCT04621630 · 107 enrolled · Australia
  3. Feb 29, 2024Named icotrokinraINNProposed as its International Nonproprietary Name in WHO's List 130 · before, JNJ-77242113, PN-235

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Protagonist Therapeutics leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04621630Healthy Volunteers · Australia1CompletedSep 19, 2021107

How it is read

Names in the registry

  • “JNJ-77242113”, 9 entries
  • “Icotrokinra”, 4 entries
  • “PN-235”, 1 entry

Codes read as this program: PN235.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.